top of page
Search
Hereditary Pancreatic Cancer Risk Management: Interpreting Surveillance Findings in High-Risk Patients
Mehul Trivedi, MD - Communications Committee Member We were delighted to welcome Dr. Fay Kastrinos, Professor of Medicine at Columbia University and Director of the GI Cancer Risk and Prevention Clinic and Pancreatic Cancer Prevention and Genetics Program, who shared her expertise on current strategies, outcomes, and emerging approaches to pancreatic cancer screening in high-risk individuals. We began by reviewing the goals of pancreatic cancer screening, emphasizing the impo
CGA-IGC
Oct 133 min read
Connecting to Latin American Genetic Counseling and Hereditary Cancer Resources This Hispanic Heritage Month!
Chandrika Kurpad, MS, LGCG - Communications Committee Member Hispanic Heritage Month provides an opportunity to recognize and celebrate the diverse communities, cultures, and contributions of Latin America. It is also an opportunity to highlight resources that support healthcare professionals working to expand knowledge, education, and access to genetic counseling and hereditary cancer care across the region. For those interested in genetic counseling, cancer genetics, and he
CGA-IGC
Oct 124 min read
Adding a COX-2 Inhibitor to Neoadjuvant Immunotherapy in dMMR/MSI-H Colorectal Cancer: What PICC-2 Tells Us
Alessandro Mannucci, MD, CGA-IGC Communications Committee Member Source: Hu H, Shen X, Li Y, et al. Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2026;27:1020–30. Why this trial matters Over the last five years, neoadjuvant PD-1 blockade has completely changed the management o
CGA-IGC
Oct 76 min read
bottom of page